

Abamectin (0.6%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.0	28.09.2024	10853357-00006	Date of first issue: 15.09.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Abamectin (0.6%) Liquid Formulation
	Other means of identification	:	COOPERS MAVERICK POUR ON FOR SHEEP (61710)
1.2	Relevant identified uses of th	ie s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 Eye irritation, Category 2 Specific target organ toxicity - repeated exposure, Category 2	H332: Harmful if inhaled. H319: Causes serious eye irritation. H373: May cause damage to organs through pro- longed or repeated exposure.
Short-term (acute) aquatic hazard, Cate- gory 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Cat- egory 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024		SDS Number: 10853357-0000	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
Hazard pictograms		:		
Signa	l word	:	Warning	• •
Hazard statements		:	H319 H332 H373 H410	Causes serious eye irritation. Harmful if inhaled. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.
Preca	uutionary statements	:	Prevention: P264 P273 P280	Wash skin thoroughly after handling. Avoid release to the environment. Wear eye protection/ face protection.
			Response: P314 P337 + P313 P391	Get medical advice/ attention if you feel unwell. 3 If eye irritation persists: Get medical advice/ attention. Collect spillage.

Hazardous components which must be listed on the label:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

Additional Labelling

EUH208 Contains 1-[1,3-Bis(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1,3bis(hydroxymethyl)urea. May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)

_

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

rsion	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.202	
		Index-No. Registration nu	Imber	
	lkylene oxide derivative o etic alcohol	of a 103818-93-5	Eye Irrit. 2; H319	>= 30 - < 50
	ectin (combination of ave n B1a and avermectin B1		Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Repr. 2; H361fd STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000	>= 0.5 - < 1
			limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0.5 - < 5 %	
dioxo	B-Bis(hydroxymethyl)-2,5- imidazolidin-4-yl]-1,3- ydroxymethyl)urea	78491-02-8 278-928-2	Eye Irrit. 2; H319 Skin Sens. 1; H317 Aquatic Chronic 3; H412	>= 0.1 - < 0.2

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air.



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024		S Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
				give artificial respiration. ficult, give oxygen. ntion.
In ca	se of skin contact	:	of water. Remove contam Get medical atte Wash clothing be	
In ca	se of eye contact	:	for at least 15 m	nove contact lens, if worn.
lf swa	allowed	:	Get medical atte) NOT induce vomiting. ntion. roughly with water.
4.2 Most i	important symptoms a	nd e	effects, both acut	te and delayed
Risks	3	:	Causes serious Harmful if inhale May cause dama exposure.	
			May produce an	allergic reaction.
4.3 Indica	tion of any immediate	meo	lical attention an	d special treatment needed
Treat	ment	:	Treat symptoma	tically and supportively.
SECTION	N 5: Firefighting mea	sur	es	
5.1 Exting	guishing media			
	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
5.2 Specia	al hazards arising from	n the	substance or m	ixture
-	ific hazards during fire-			ubustion products may be a hazard to health.
			.	

Hazardous combustion prod- : Carbon oxides ucts



Version 4.0	Revision Date: 28.09.2024		DS Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
5.3 Advice	e for firefighters			
Special protective equipment for firefighters		:		e, wear self-contained breathing apparatus. tective equipment.
Speci ods	Specific extinguishing meth- ods		cumstances and to Use water spray to	measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

Environmental precautions	
-	Prevent further leakage or spillage if safe to do so.
	Prevent spreading over a wide area (e.g. by containment or oil
	barriers).
	Retain and dispose of contaminated wash water.
	Local authorities should be advised if significant spillages
	cannot be contained.

6.3 Methods and material for containment and cleaning up

:

Methods for cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent.
		Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures

See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

Versio 4.0	on	Revision Date: 28.09.2024		DS Number: 0853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022			
L	.ocal/T	otal ventilation	:	: If sufficient ventilation is unavailable, use with local exhau ventilation.				
Advice on safe handling Hygiene measures		:	Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the					
				use of administra				
7.2 Co	onditi	ons for safe storage,	inc	luding any incom	patibilities			
Requirements for storage areas and containers		:		labelled containers. Keep tightly closed. ell-ventilated place. Store in accordance with ional regulations.				
А	\dvice	on common storage	ge : Do not store with the following pro Strong oxidizing agents Gases					
7.3 Sp	pecific	c end use(s)						
-		c use(s)	:	No data available				

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL
		OELV - 8 hrs (TWA) (total (va- pour and parti- cles))	150 ppm 470 mg/m3	IE OEL
abamectin (combi- nation of avermec-	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.20 Date of first issue: 15.09.20	
	a and aver- n B1b) (ISO)			
		Wipe limit	150 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

	. ,			
Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
1-[1,3- Bis(hydroxymethyl)- 2,5-dioxoimidazolidin- 4-yl]-1,3- bis(hydroxymethyl)ure a	Workers	Inhalation	Long-term systemic effects	20.5 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	92 mg/m3
	Workers	Dermal	Long-term systemic effects	11.7 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57.2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)
1-[1,3-Bis(hydroxymethyl)-2,5- dioxoimidazolidin-4-yl]-1,3- bis(hydroxymethyl)urea	Fresh water	5.78 μg/l
	Freshwater - intermittent	57.8 μg/l
	Marine water	0.58 µg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	0.0888 mg/kg dry weight (d.w.)
	Marine sediment	0.0089 mg/kg dry weight (d.w.)
	Soil	0.0144 mg/kg dry



Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022	

weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143 Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	clear
		dark blue
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versio 4.0	on	Revision Date: 28.09.2024		S Number: 353357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
	nitial bo ange	oiling point and boiling	:	No data available	3
F	-lamma	ability (solid, gas)	:	Not applicable	
F	-lamma	ability (liquids)	:	No data available)
		explosion limit / Upper bility limit	:	No data available	3
		explosion limit / Lower bility limit	:	No data available	
F	-lash p	oint	:	No data available	3
A	Auto-igi	nition temperature	:	No data available	9
Γ	Decom	position temperature	:	No data available)
þ	эΗ		:	No data available	9
١	√iscosit Visc	ty osity, kinematic	:	No data available)
ŝ	Solubili Wate	ty(ies) er solubility	:	No data available)
	Partition octanol	n coefficient: n- /water	:	Not applicable	
١	√apour	pressure	:	No data available	
F	Relative	e density	:	No data available)
[Density		:	No data available)
F	Relative	e vapour density	:	No data available)
F		characteristics icle size	:	Not applicable	
	ther in Explosi	formation ves	:	Not explosive	
C	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
E	Evapora	ation rate	:	No data available	
Ν	Molecu	lar weight	:	No data available	3



Abamectin (0.6%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.0	28.09.2024	10853357-00006	Date of first issue: 15.09.2022

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity		
Harmful if inhaled.		
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 3.83 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versio 4.0	n Revision Date: 28.09.2024		DS Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
II			LD50 (Mouse): 10) mg/kg
			LDLo (Monkey): 2 Symptoms: Dilata	
A	cute inhalation toxicity	:	LC50 (Rat): 0.023 Exposure time: 4 Test atmosphere:	h
A	cute dermal toxicity	:	LD50 (Rat): 330 r	ng/kg
			LD50 (Rabbit): 2,	000 mg/kg
		2,5-0		-4-yl]-1,3-bis(hydroxymethyl)urea:
A	cute oral toxicity	:	LD50 (Rat): > 2,0 Method: OPPTS 8	
A	cute dermal toxicity	:	LD50 (Rabbit): > Method: OPPTS & Assessment: The toxicity	
P S	omponents: olyalkylene oxide derivativ pecies	ve o	reconstructed hur	man epidermis (RhE)
	lethod esult	:	OECD Test Guide	eline 439
IK	esuit	:	No skin irritation	
	bamectin (combination of	ave		avermectin B1b) (ISO):
	pecies esult	:	Rabbit No skin irritation	
1-	[1,3-Bis(hydroxymethyl)-2	2,5-0	lioxoimidazolidin∙	-4-yl]-1,3-bis(hydroxymethyl)urea:
	pecies esult	:	Rabbit No skin irritation	
	erious eye damage/eye irri auses serious eye irritation.	itati	on	
	omponents:			
P	olyalkylene oxide derivativ	/e o	f a synthetic alco	hol:
S	pecies lethod	:	Bovine cornea OECD Test Guide	



Version 4.0	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.202410853357-00006Date of first issue: 15.09.2022			
Resul	Result : Irritation to eyes, reversing within 21 days				
abam Speci Resul	of avermectin B1a and avermectin B1b) (ISO): : Rabbit : Mild eye irritation				
Speci	1-[1,3-Bis(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)ureaSpecies:RabbitResult:Irritation to eyes, reversing within 21 days				
Resp	iratory or skin sensi	isation			
Not cl Resp i	Skin sensitisation Not classified based on available information. Respiratory sensitisation Not classified based on available information.				
abam Test 1	ectin (combination of Type sure routes	of avermectin B1a and avermectin B1b) (ISO): : Maximisation Test : Skin contact : Not a skin sensitizer.			
Test	Type sure routes	 -2,5-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)urea: Human repeat insult patch test (HRIPT) Skin contact positive 			
Asses	ssment	: Probability or evidence of skin sensitisation in humans			
Not cl	a cell mutagenicity assified based on ava conents:	ilable information.			
	•	of avermectin B1a and avermectin B1b) (ISO):			
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative			
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative			
		Test Type: Alkaline elution assay Result: negative			
Geno	toxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse			
		12 / 24			



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
		Application Rou Result: negative	ute: Intraperitoneal injection e
1-[1,3	-Bis(hydroxymethyl)-	2,5-dioxoimidazolid	in-4-yl]-1,3-bis(hydroxymethyl)urea:
Geno	toxicity in vitro		terial reverse mutation assay (AMES) Test Guideline 471 e
			tro mammalian cell gene mutation test Test Guideline 476
		Test Type: Chro Result: negative	omosome aberration test in vitro e
			A damage and repair, unscheduled DNA syn- nalian cells (in vitro) e
Geno	toxicity in vivo	: Test Type: Mar cytogenetic ass Species: Mouse Application Rou Result: negative	e ite: Ingestion
		mammalian live Species: Rat Application Rot	ute: Ingestion Test Guideline 486

Carcinogenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rat
Application Route	: Oral
Exposure time	: 105 weeks
Result	: negative
Species	: Mouse
Application Route	: Oral
Exposure time	: 93 weeks
Result	: negative

Reproductive toxicity

Not classified based on available information.



4.0 28.09.2024 10853357-00006 Date of first issue: 15.09.2022	Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
---	----------------	---------------------------	-------------------------------	---

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility	: Test Type: Fertility Species: Rat, male Application Route: Oral Result: Effects on fertility
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: NOAEL: 0.12 mg/kg body weight Result: Fetotoxicity
Effects on foetal develop- ment	 Test Type: Embryo-foetal development Species: Mouse Application Route: Oral General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Cleft palate Remarks: Adverse developmental effects were observed
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic survival Remarks: Adverse developmental effects were observed
	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 1.6 mg/kg body weight Result: Teratogenic effects
Reproductive toxicity - As- sessment	Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.
1-[1,3-Bis(hydroxymethyl)-2,5	-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)urea:
Effects on foetal develop-	: Test Type: Embryo-foetal development

Effects on foetal develop- ment	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative
		Test Type: Embryo-foetal development Species: Rat Application Route: Skin contact Result: negative



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.0	28.09.2024	10853357-00006	Date of first issue: 15.09.2022

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes Target Organs

- : Ingestion
- Assessment
- Central nervous system
 Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species NOAEL Application Route Exposure time Target Organs Symptoms	 Rat 1.5 mg/kg Oral 24 Months Central nervous system Tremors, ataxia
Species NOAEL Application Route Exposure time Target Organs Symptoms	 Mouse 4.0 mg/kg Oral 24 Months Central nervous system Tremors, ataxia
Species NOAEL LOAEL Application Route Exposure time Target Organs Symptoms Remarks	 Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervous system Tremors, weight loss mortality observed
Species NOAEL Application Route Exposure time Target Organs	: Monkey : 1.0 mg/kg : Oral : 14 Weeks : Central nervous system

1-[1,3-Bis(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)urea:

Species NOAEL	: Rat
NOAEL	: 200 mg/kg

Revision Date:

Version

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Date of last issue: 06.04.2024

Abamectin (0.6%) Liquid Formulation

4.0	28.09.2024	108	353357-00006	Date of first issue: 15.09.2022			
A	pplication Route xposure time	:	Ingestion 92 Days				
A	spiration toxicity						
N	Not classified based on available information.						
11.2 lı	11.2 Information on other hazards						
E	Endocrine disrupting properties						
<u>P</u>	Product:						
A	ssessment	:	ered to have en REACH Article	mixture does not contain components consid- docrine disrupting properties according to 57(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at r higher.			
E	Experience with human exposure						
<u>C</u>	Components:						
а	abamectin (combination of avermectin B1a and avermectin B1b) (ISO):						

SDS Number:

	())))))))))	
Ingestion	:	Symptoms: May cause, Tremors, Diarrhoea, central nervous
		system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

Polyalkylene oxide derivative of a synthetic alcohol:

Toxicity to fish	:	LC50 : > 1 - 10 mg/l Exposure time: 96 h Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 3.2 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish	 LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 μg/l Exposure time: 96 h
	LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l Exposure time: 96 h
	LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
	LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ion	Revision Date: 28.09.2024			Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
				n variegatus (sheepshead minnow)): 15 µg/l S h
		:		
				agna (Water flea)): 0.34 μg/l } h
Toxicity plants	v to algae/aquatic	:	mg/l	chneriella subcapitata (green algae)): 100 2 h
M-Facto icity)	or (Acute aquatic tox-	:	10,000	
Toxicity	to microorganisms	:	Exposure time: 3	ĥ
Toxicity icity)	to fish (Chronic tox-	:		2 d ales promelas (fathead minnow)
aquatic	invertebrates (Chron-	:		l d magna (Water flea)
			Exposure time: 28	
		:	10,000	
1-[1,3-E	Bis(hydroxymethyl)-2	, 5- d	lioxoimidazolidin-	4-yl]-1,3-bis(hydroxymethyl)urea:
		:	LC50 (Lepomis m	acrochirus (Bluegill sunfish)): > 67 mg/l
		:		
Toxicity plants	v to algae/aquatic	:	mg/l Exposure time: 72	chneriella subcapitata (green algae)): 5.78 2 h on (EC) No. 440/2008, Annex, C.3
			mg/l Exposure time: 72	rchneriella subcapitata (green algae)): 1.6 2 h on (EC) No. 440/2008, Annex, C.3
	Toxicity aquatic Toxicity plants M-Fact icity) Toxicity Toxicity aquatic ic toxici M-Fact ic toxicity 1-[1,3-I Toxicity Toxicity Toxicity	28.09.2024 Toxicity to daphnia and other aquatic invertebrates Toxicity to algae/aquatic plants M-Factor (Acute aquatic tox- icity) Toxicity to microorganisms Toxicity to fish (Chronic tox- icity) Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity) M-Factor (Chronic aquatic toxicity) M-Factor (Chronic aquatic toxicity) M-Factor (Chronic aquatic toxicity) Toxicity to fish Toxicity to fish Toxicity to daphnia and other aquatic invertebrates Toxicity to algae/aquatic	28.09.202410Toxicity to daphnia and other aquatic invertebrates:Toxicity to algae/aquatic plants:M-Factor (Acute aquatic tox- icity):Toxicity to microorganisms:Toxicity to fish (Chronic tox- icity):Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity):M-Factor (Chronic aquatic toxicity):M-Factor (Chronic aquatic toxicity):M-Factor (Chronic aquatic toxicity):M-Factor (Chronic aquatic toxicity):Toxicity to daphnia and other toxicity to fish:Toxicity to fish:Toxicity to daphnia and other toxicity to fish:Toxicity to daphnia and other aquatic invertebrates:Toxicity to daphnia and other aquatic invertebrates:	28.09.202410853357-00006LC50 (Cyprinodor Exposure time: 96Toxicity to daphnia and other aquatic invertebrates:EC50 (Americamy Exposure time: 96Toxicity to algae/aquatic plants:EC50 (Daphnia m Exposure time: 72M-Factor (Acute aquatic tox- icity):10,000Toxicity to microorganisms:EC50 : > 1,000 m Exposure time: 3 Test Type: RespirToxicity to fish (Chronic tox- icity):NOEC: 0.52 µg/l Exposure time: 32 Species: PimephaToxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity):NOEC: 0.03 µg/l Exposure time: 22 Species: MysidopM-Factor (Chronic aquatic toxicity):10,000NOEC: 0.035 µg Exposure time: 22 Species: MysidopM-Factor (Chronic aquatic toxicity):10,00011,1.3-Bis(hydroxymethyl)-2,5-dioxoimidazolidin- Toxicity to daphnia and other aquatic invertebrates:10,000Toxicity to algae/aquatic plants:EC50 (Daphnia m Exposure time: 24 Species: MysidopM-Factor (Chronic aquatic toxicity)::10,000Toxicity to fish aquatic invertebrates::10,000Toxicity to algae/aquatic plants:::Toxicity to algae/aquatic plants:::Toxicity to algae/aquatic plants:::Toxicity to algae/aquatic plants:::Toxicity to algae/aquatic plants:::Toxicity to algae/aquatic plants::



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024		OS Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
Toxici	ty to microorganisms	:	Exposure time: 3	
12.2 Persis	stence and degradabil	ity		
<u>Comp</u>	onents:			
Polya	Ikylene oxide derivativ	/e c	f a synthetic alco	hol:
Biode	gradability	:	Result: Readily bi Remarks: Based	iodegradable. on data from similar materials
abam	ectin (combination of	ave	rmectin B1a and a	avermectin B1b) (ISO):
Stabili	ty in water	:	Hydrolysis: 50 %((< 12 h)
1-[1,3-	-Bis(hydroxymethyl)-2	2,5-0	lioxoimidazolidin	-4-yl]-1,3-bis(hydroxymethyl)urea:
Biode	gradability	:	Result: Not readil Biodegradation: 2 Exposure time: 28 Method: Directive	24 %
12.3 Bioac	cumulative potential			
Comp	onents:			
	ectin (combination of			avermectin B1b) (ISO):

Bioaccumulation	:	Bioconcentration factor (BCF): 52
Partition coefficient: n- octanol/water	:	log Pow: 4

1-[1,3-Bis(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)urea:

Partition coefficient: n-	:	log Pow: < 0.9
octanol/water		Method: OECD Test Guideline 117

12.4 Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ- : log Koc: > 3.6 mental compartments

12.5 Results of PBT and vPvB assessment

Product:

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or
		very persistent and very bioaccumulative (vPvB) at levels of
		0.1% or higher.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.0	28.09.2024	10853357-00006	Date of first issue: 15.09.2022

12.6 Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number		
ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
ΙΑΤΑ	:	UN 3082
14.2 UN proper shipping name		
ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))



Version 4.0	Revision Date: 28.09.2024		9S Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
IMI)G	:	N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID, bination of avermectin B1a and avermectin
ΓΑΙ	A	:		hazardous substance, liquid, n.o.s. bination of avermectin B1a and avermectin
14.3 Tra	insport hazard class(es)			
			Class	Subsidiary risks
AD	N	:	9	
AD	R	:	9	
RIC)	:	9	
IMI)G	:	9	
ΙΑΙ	A	:	9	
14.4 Pa	cking group			
Cla Ha: Lat Pao Cla Ha: Lat Pao Cla Ha: Lat IMI Pao Lat	cking group ssification Code zard Identification Number bels R cking group ssification Code zard Identification Number bels nel restriction code cking group ssification Code zard Identification Number bels		III M6 90 9 III M6 90 9 (-) III M6 90 9 9 III 9 5 F-A, S-F	
Pao airc Pao Pao Lat IA1 Pao	A (Cargo) cking instruction (cargo traft) cking instruction (LQ) cking group bels A (Passenger) cking instruction (passen- aircraft)	: : : : : : : : : : : : : : : : : : : :	964 Y964 III Miscellaneous 964	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024		DS Number: 1853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
	ng instruction (LQ) ng group s	:	Y964 III Miscellaneous	
14.5 Envir	onmental hazards			
ADN Enviro	onmentally hazardous	:	yes	
ADR Enviro	onmentally hazardous	:	yes	
RID Enviro	onmentally hazardous	:	yes	
IMDG Marin	e pollutant	:	yes	

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks	Not applicable for product as supplied
Remains	Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
		Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) REACH - Restrictions on the manufacture, placing on		Number on list 77: 1-[1,3- Bis(hydroxymethyl)-2,5- dioxoimidazolidin-4-yl]-1,3- bis(hydroxymethyl)urea
the market and use of certain dangerous substances, mixtures and articles (Annex XVII)		
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin (0.6%) Liquid Formulation

Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006			ue: 06.04.20 sue: 15.09.20	
				cable	to the placing	g on the market or
				not.		
	ACH - Candidate List of ncern for Authorisation (A		lh	Not ap	plicable	
	gulation (EC) on substan	,	one	Not ap	plicable	
Re	gulation (EU) 2019/1021 ts (recast)	on persistent organic p	ollu-	Not ap	plicable	
Re me	gulation (EU) No 649/20 ² Int and the Council conce dangerous chemicals		Not ap	oplicable		
RE	ACH - List of substances	subject to authorisation	n	Not ap	plicable	
Se	veso III: Directive 2012/1 jor-accident hazards invo		it and of	the Council	on the control of	
	,			Qua	ntity 1	Quantity 2

		Quantity I	Quantity Z
E1	ENVIRONMENTAL	100 t	200 t
	HAZARDS		

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H300	:	Fatal if swallowed.
H311	:	Toxic in contact with skin.
H317	:	May cause an allergic skin reaction.
H319	:	Causes serious eye irritation.
H330	:	Fatal if inhaled.
H361fd	:	Suspected of damaging fertility. Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.



Version 4.0	Revision Date: 28.09.2024		OS Number: 853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022		
H412	H412		: Harmful to aquatic life with long lasting effects.			
Full text of other abbreviation						
Aqua Aqua Eye Repr Skin STO	Acute Tox. Aquatic Acute Aquatic Chronic Eye Irrit. Repr. Skin Sens. STOT RE IE OEL		Eye irritation Reproductive tox Skin sensitisation Specific target or Ireland. List of Ch	ic) aquatic hazard city		
IE OEL / OELV - 8 hrs (TWA)				osure limit value (8-hour reference period)		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/



Version 4.0	Revision Date: 28.09.2024	SDS Number: 10853357-00006	Date of last issue: 06.04.2024 Date of first issue: 15.09.2022
Class	sification of the mixt	ure:	Classification procedure:
Acute	e Tox. 4	H332	Calculation method
Eye lı	rrit. 2	H319	Calculation method
STOT	TRE 2	H373	Calculation method
Aquat	tic Acute 1	H400	Calculation method
Aquat	tic Chronic 1	H410	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN